Sulistyaningsih Erma, Wibisono Renaldi, Dewi Rosita
Department of Parasitology, Faculty of Medicine, University of Jember, Jember 68121, Indonesia.
Center of Excellence of Agromedicine (CEAMED), University of Jember, Jember 68121, Indonesia.
Trop Med Infect Dis. 2022 Sep 2;7(9):222. doi: 10.3390/tropicalmed7090222.
The malaria vaccine is an important strategy for the global malaria elimination program, but the complexity of the Plasmodium antigen is a major hurdle in malaria vaccine development. The cysteine-rich interdomain region 1α (CIDR1α) of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is crucial in malaria pathogenesis, making it a vaccine candidate. This study investigated the leukocyte and IgM response generated after administering a CIDR1α-PfEMP1 recombinant protein injection in Wistar rats. The rats were divided into a control group, who received a physiological saline solution (PSS), and a treatment group, who were subcutaneously injected with 150 µg of purified CIDR1α-PfEMP1 protein three times at the 3-week interval. Blood samples were collected every week after each injection. The number of leukocytes were counted using a Neubauer chamber, and the IgM concentration was determined using an enzyme-linked immunosorbent assay (ELISA). Data were analyzed using an independent, paired-T test, a Mann−Whitney test, and a Wilcoxon test, based on the distribution of the data. The total number of leukocytes notably increased on day 29 (p < 0.05). The percentage of neutrophils decreased, especially on day 8 (p < 0.05), whereas the percentages of monocytes and lymphocytes increased, primarily on day 14 (p < 0.05). The IgM concentration increased on day 14 (p < 0.05). In conclusion, the CIDR1α-PfEMP1 recombinant protein may induce leukocyte and IgM responses, making it a potential malaria vaccine candidate.
疟疾疫苗是全球疟疾消除计划的一项重要策略,但疟原虫抗原的复杂性是疟疾疫苗研发的一个主要障碍。恶性疟原虫红细胞膜蛋白1(PfEMP1)富含半胱氨酸的结构域间区域1α(CIDR1α)在疟疾发病机制中至关重要,使其成为一种疫苗候选物。本研究调查了在Wistar大鼠中注射CIDR1α-PfEMP1重组蛋白后产生的白细胞和IgM反应。将大鼠分为对照组(接受生理盐水溶液)和治疗组(每隔3周皮下注射150μg纯化的CIDR1α-PfEMP1蛋白3次)。每次注射后每周采集血样。使用血细胞计数板计数白细胞数量,使用酶联免疫吸附测定(ELISA)测定IgM浓度。根据数据分布,使用独立样本t检验、配对t检验、Mann-Whitney检验和Wilcoxon检验对数据进行分析。白细胞总数在第29天显著增加(p<0.05)。中性粒细胞百分比下降,尤其是在第8天(p<0.05),而单核细胞和淋巴细胞百分比增加,主要在第14天(p<0.05)。IgM浓度在第14天增加(p<0.05)。总之,CIDR1α-PfEMP1重组蛋白可能诱导白细胞和IgM反应,使其成为一种潜在的疟疾疫苗候选物。